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Pancreatic ductal adenocarcinoma (PDAC), with a 5-year survival of less than 5%, remains a major 
challenge in oncology. High levels of the calcium-binding protein S100P are found in PDAC; S100P 
enhances cell survival, proliferation and invasion through interactions with intracellular targets and via 
extracellular interaction with the receptor for advanced glycation end products (RAGE).  Previous in 
vivo studies have shown that inhibition or silencing of S100P reduces tumour growth and metastasis, 
and enhances response to gemcitabine therapy.  As such, S100P has emerged as a promising 
biological target for novel anticancer drug design.   
Computational modelling of a small-molecule binding site in S100P was used in a virtual screen to 
identify hit compounds, predicted to bind S100P and inhibit its tumour-promoting effects. This study 
aims to develop a screening technique to rapidly identify S100P-inhibiting compounds, to aid 
development of a novel therapy for PDAC.  An enzyme linked immunosorbent assay (ELISA), to detect 
S100P-RAGE binding, was developed based on a published protocol; hit compounds (purchased or 
synthesised in-house) were then screened for inhibition of S100P-RAGE interaction. Ninety-three 
compounds, at concentrations ranging from 1nM-1μM, were screened in triplicate (n=9). 18 compounds 
with statistically significant S100P/RAGE inhibition were selected from this assay and tested for their 
effects on cells using MTS (metabolic activity) and LDH release (cell toxicity) assays. Transwell 
migration and invasion assays were performed on two human pancreatic cancer cell lines; S100P-
overexpressing cells (BxPC-3) and cells not expressing S100P (Panc-1), to assess the effects of 
treatment with hit compounds.  
MTS and LDH release assays revealed that the compounds did not exhibit general cytotoxicity. For 13 
of 18 compounds, BxPC-3 cells treated for 48 hours at (10µM); demonstrated a significant reduction in 
cell invasion but there was no effect on Panc-1 cells; evidence of an S100P-specific mechanism.   
In conclusion, results from this study confirm that the measurement of S100P-RAGE binding by ELISA 
can be used as a screen to identify compounds that have functional effects in S100P-expressing 
pancreatic cancer cells and enable further development of a potential therapy for pancreatic cancer.  
 
